Wells Fargo & Company Aquestive Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 24,065 shares of AQST stock, worth $77,008. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,065
Previous 14,323
68.02%
Holding current value
$77,008
Previous $28,000
264.29%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AQST
# of Institutions
105Shares Held
42.1MCall Options Held
463KPut Options Held
431K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$31.4 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$17.8 Million2.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$10.4 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.22MShares$7.1 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY1.55MShares$4.94 Million0.06% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $171M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...